A new pancreatic cancer vaccine seemed to slow the progression of the disease and to increase survival in patients in an early study.
Pancreas cancer has some of the poorest survival rates, since this is often only detected in an advanced stage.
Many see that despite treatments such as chemotherapy and radiation therapy, their cancer do not respond to treatment or spread further.
The new vaccine, which promised in an early study with 20 pancreas cancer patients and five with colon cancer, was developed to help the body’s immune system to find and attack cancer cells.
Both pancreatic and intestinal cancer have a mutation in a gene called Kras that plays a key role in tumor growth.
The JAB was developed to identify and attack crab cells with crashing crayfish cells and to improve the vaccine levy to the lymph nodes that filter out foreign substances such as cancer cells and infections.
In the phase -1 study for the JAB, 68% of the 25 patients had developed a strong immune response to the mutated Kras tumor proteins after about 20 months.
However, some patients answered cheaper than others. Experts said that more research was necessary to determine the cause of the different reactions.
Those with the strongest immune response both lived longer and remained for longer cancer -free than those with a weaker reaction.
According to the study published in the Nature Medicine magazine, Pancreas cancer patients survived, which received the vaccine, about two years and five months after receiving the ELI-002 2p Jab.
Currently only three out of ten people survive for a year, so the results of the early studies give the patient new hope.
Read more from Sky News:
Amber heat health warning for parts of England
30 evacuated according to Burst Water main flood streets flooded streets
The vaccine does not have to be personalized and can therefore be manufactured in the mass in order to be administered faster.
The researchers have already started testing the effectiveness of the stab under a larger group of pancreatic and intestinal cancer patients.
The study leads Dr. ZEV Wainberg from the University of California in the US city of Los Angeles as “remarkable” and said that the second phase of the experiment was already underway.